Member Info for maximillion69

Https://x.com/imgbiometrics/status/1945468463281311951?s=46

Got ya Semantic

Show jumper

The buying started yesterday afternoon 🤞

It definitely would be a shocker if KS reduced !

Paladin

Likewise with Synairgen big losses for myself.

I still hold within private set up but hold no optimism .

I’d put most of that down To MS

Https://x.com/imgbiometrics/status/1943390905316315589?s=46

Tyke

The basket case quote is one of Semantics

Let’s hope this rise continues and semantics words come to Fruition . 😄

Hold on Semantic

The concerns which fail are those which have scattered their capital, which means that they have scattered their brains also. They have investments in this, or that, or the other, here, there and everywhere. “Don’t put all your eggs in one basket” is all wrong. I tell you “put all your eggs in one basket, and then watch that basket.” Look round you and take notice; men who do that do not often fail. It is easy to watch and carry the one basket. It is trying to carry too many baskets that breaks most eggs in this country. He who carries three baskets must put one on his head, which is apt to tumble and trip him up

Thanks howdlep

Little jump in SP. Maybe more Directors

Presume now no known news for a month .

Paladin

I think from your post you expressed concern of GaM and benefits to IB if approval was granted in the future me too , but of digging highlights the bonus of Orphan Drug Designation

AI

Companies with orphan drug designation often receive a period of market exclusivity, typically 10 years in the EU/EEA and UK and 7 years in the US, during which similar drugs for the same indication cannot be approved. This provides a competitive advantage and protects the company's investment in developing the drug

Nice find

PR , PR and more PR !

GE come throw some dollar our way !

Bio

I put a latest link on for you ,

Congressman Gus Bilirakis (FL-09): “One important tool in promoting drug development is the FDA's Rare Pediatric Disease Designation and Priority Review Voucher Program, which has led to the approval of over 50 treatments for 39 different rare, pediatric diseases - 36 of which had no FDA approval treatments before the program began. I was very pleased to see the president's FDA budget allocate funding for this priority review voucher program, and I have bipartisan legislation that would fully reauthorize the program for years to come.”

Imaging side sales to me is a worry , we see MS and KS doing plenty presentations we also know many trials are using or tech but I’m not sure institutions are pushing it for it . There is also the worry of other technologies rapidly developing .

Https://energycommerce.house.gov/posts/health-subcommittee-holds-hearing-on-hhs-fiscal-year-2026-budget

Https://x.com/imgbiometrics/status/1938627024014152108?s=46

Https://www.linkedin.com/posts/carl-vincent-0448b9142_innovation-sustainability-speedydoesit-activity-7344317138121220096-6Lcx?utm_source=share&utm_medium=member_ios&rcm=ACoAAAkyjQ0B7bMMkoLn8XD8s2HLk9vizWE-zfc

At the moment

We have 2 websites

In addition to

Imaginebiometrics

ibaiLtd.com.

Updated iqai site

I’d imagine new website will consolidate the 2